|Articles|September 25, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC
2
‘Full House’ Star Dave Coulier Talks Tongue Cancer Diagnosis
3
FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer
4
Padcev/Keytruda Combo Extends Survival in Muscle-Invasive Bladder Cancer
5